2024 yanga iri shanduko-yemutambo weCAR T-Cell kurapwa muChina! Pupurira nyaya dzebudiriro dzinoshamisa kubva kuzviyedzo zvekiriniki, ongorora kufambira mberi, uye dzidza nezvematambudziko asara. Huya utsvage ramangwana rekurapa kwegomarara uku kuri kupa mamirioni avanhu tariro zvakare!
Sayenzi yakawedzera zvinoshamisa munyaya yezvokurapa. Mumakore mashoma apfuura, takaona akawanda matsva ekurapa uye zvinodhaka zvinoshanda sechipo kune varwere vanorwara nezvirwere zvakakomba sekenza. Gomarara rinoramba riri dambudziko rehutano hwepasi rose, richikanganisa mamirioni ehupenyu gore rega rega.
IAmerican Cancer Society (ACS) inofungidzira 1,958,310 nyowani kenza kenza muna 2023, kusanganisa isiri-melanoma ganda cancer. Zvinosuruvarisa, vanopfuura 609,820 vafa negomarara vakaverengerwa gore rimwe chete.
CAR-T cell therapy ndeyepamusoro immunotherapy iyo inodzidzisa immune system yako kuona uye kuparadza maseru egomarara nekunyatsoona.
Iyi haisi ngano yesainzi; ndicho chokwadi chekupedzisira cheCAR T cell kurapwa, shanduko yekudzivirira-yakavakirwa nzira iyo iri kuunza mufaro mukuru mukurwisa cancer.
Ndichiri mumatanho ekutanga, CAR T cell kurapa yakaratidza vimbiso inoshamisa mukurapa chaiwo gomarara reropa, netsvakiridzo inoenderera ichitarisa kugona kwayo kurapa marudzi akasiyana emamota.
Muchinyorwa chino, isu tichaongorora pasi-inopwanya CAR T Cell kurapwa kliniki miedzo muChina, nzvimbo huru dzekutarisa, uye kurukurai matambudziko nemikana inonakidza inoumba ramangwana reiyi shanduko yekurapa.
Verenga Izvi: Kiyi yeKubudirira kweCAR-T Iri Mukusarudza Kwemurwere - Ndiwe Wakakodzera Here?
Milestones Munhoroondo yeCAR T Cell Therapy MuChina
Rwendo rwe CAR T Cell Therapy MuChina inofanana nenhangemutange kubva kumabhuroki ekutanga, nekufambira mberi kunoshamisa uye vavariro.
Kubudirira Kwekupayona (2013): China yakashuma yekutanga CAR T-cell kurapa yeB-ALL yakananga CD19 muna 2013, zvichiratidza budiriro yekutanga mukutorwa kwenyika kweCAR T-cell tekinoroji.
Rapid Evolution (2017-2019): Pakupera kwegore ra2017, China yakabuda senyika ine nhamba yepamusoro yeCAR-T cell kiriniki miedzo, ichiratidza kukurumidza kushanduka uye kudyara kwakakosha mune iyi nzira yekurapa.
Kuenderera mberi Kunoenderera mberi (2022): Mumakore mashoma akapfuura, CAR T cell kurapwa kwegomarara muChina yakaratidza kushanda kunoshamisa mukurapa gomarara rehematological, zvichiratidza kuenderera mberi.
Unofanira Kuverenga: Basa reImmunotherapy Mukurapa Lymphoma - CancerFax
Yemahara CAR T Cell Therapy Clinical Miedzo MuChina: Tariro Kune Vese
Muchirongwa chinokatyamadza, China parizvino iri kupa kurapwa kenza pasina muChina, zvichipa tariro itsva kuvarwere vari kurwisana nemamwe marudzi ekenza. Zvipatara zvine mukurumbira zvakaita sePeking University Cancer Hospital, Sun Yat-sen University Cancer Center, West China Hospital, First Affiliated Hospital yeZhengzhou University, Beijing Gorboad Boren Hospital, uye zvimwe zvakawanda zviri kuita muyedzo idzi.
Zvidzidzo zvekiriniki zvine chinangwa chekurapa akawanda myeloma, B-cell acute lymphoblastic leukemia (ALL), uye B-cell diffuse hombe B-cell lymphoma (DLBCL). Varwere vane idzi mhando dzegomarara vanogona ikozvino kuongorora yepamusoro CAR T cell kurapwa pasina mutoro wemari. Ichi chirongwa hachingowedzera kuwanikwa kwekurapa kutsva asiwo chinoisa China semutungamiri wepasi rose mukutsvaga nekurapa cancer.
Mhedzisiro Yetsvagiridzo Yezvino PaCAR T Cell Therapy Clinical Trials MuChina
Tsvagiridzo yeCAR T cell therapy iri kufambira mberi nekukurumidza muChina, uko miedzo yekiriniki yakawanda iri kuongorora kugona kwekurapa kwemhando dzakasiyana dzegomarara. Imwe nzvimbo inonakidza ndeye maviri-anonangwa eCAR T masero, achibatanidza kurwiswa kweakawanda maantigen egomarara kuitira kuwedzera kushanda.
Miyedzo yekutanga ine CD19/20 yakanangana lymphoma yakaratidza mwero wekupindura wakatanhamara, ichigadzira nzira yekumwe kuongorora.
Phase-2 tsvakurudzo ye-anti-CD19 uye anti-CD22 CAR T masero anopesana neB-cell acute lymphoblastic leukemia (ALL) yakawana yakanakisa 88% yehuwandu hwekupindura mwero mumwongo uye 85% mukati mepakati tsinga system.
Kupfuura iyo yakajairwa CD19 chinangwa, vaongorori vari kuongorora nzvimbo dzisina kuongororwa. Miedzo inosanganisira BCMA, CD20, uye GPC3 iri kuburitsa zvinogoneka mumhando dzakasiyana dzegomarara, zvichiratidza kuchinjika kwemaitiro ekurapa aya.
Zvisinei, kuchengeteka kuchiri kunetseka zvikuru. Cytokine kuburitsa chirwere (CRS) inogona kuve yakaoma zvikuru, kusunda vaongorori kuti vape mhinduro dzakaita seyakagadziridzwa CAR dhizaini uye musanganiswa kurapa kuvandudza manejimendi.
Nepo China ichitungamira maererano nemiedzo inoenderera mberi, marapirwo maviri eCAR T chete akatenderwa: axicabtagene ciloleucel uye relmacabtagene autoleucel, zvichiratidza matambudziko ekusvikika nekuda kwezvirambidzo zvekudzora uye zvehupfumi.
China iri kutungamira nzira muCAR T-cell therapy innovation, kugadzirisa zvinetswa zvekuchengetedza, uye kuongorora zvinyowani zvinangwa uye mbiri-yakananga. Kunyangwe pachine zvipingamupinyi munzira yekuwanda kwevarwere kuwana, remangwana rekurapa kwekuchinja-mutambo uyu rakajeka.
Wana Kunzwisisa: Kunyura Kwakadzika MuCAR T Cell Therapy: Inoshanda Sei?
Nzvimbo Dzakakosha dzekufambira mberi muChimeric Antigen Receptor T-Cell Therapy muChina
Targeting Solid Tumors
Dambudziko: Sechivanhu, marapirwo eCAR T aratidza kubudirira kukuru mu kanzura yeropa kupfuura mamota akasimba nekuda kwekuoma kwebundu microenvironments uye antigen heterogeneity.
Kufambira mberi: Miedzo yakati wandei yeChinese iri kutarisa nzira nyowani dzekunangana nemamota akasimba.
Miedzo inoongorora masero eCAR T anoratidza maviri akasiyana receptors uye anonangana akati wandei bundu antigens kuti awedzere kushanda (semuenzaniso, BCMA/CD19 yeakawanda myeloma, GD2/NGFR ye neuroblastoma).
Zvidzidzo zviri kutarisa mune yakasarudzika TIL-yakavakirwa CAR T masero akagadzirirwa bundu remurwere wega wega, ane zvinokurudzira zvinokonzeresa mukenza yemapapu uye. melanoma.
Kubatanidza masero eCAR T nemamwe marapirwo akadai sechekipoint inhibitors kana radiation ine mukana wekuvandudza mhinduro uye kukunda kuramba mumamota akasimba.
Semuyenzaniso: Chiyedzo chePhase I (NCT05424241) uchishandisa kaviri CAR T sero kunanga BCMA uye CD19 mune relapsed/refractory multiple myeloma yakawana inokurudzira kuchengetedzwa uye kubudirira kuwanikwa, kusanganisira mhinduro dzakazara mune vamwe varwere.
Kukunda Matambudziko EToxicity
Challenge: Cytokine release syndrome (CRS) uye neurotoxicity yakakomba migumisiro yeCAR T therapy iyo inomutsa kunetseka kwekuchengeteka.
budiriro: Vatsvagiri veChinese vari kutsvaga matekiniki ekurapa uye kuderedza huturu uhu:
Miedzo iri kuitwa pamaseru eCAR T ane shanduko dzakadai se "majini ekuzviuraya" kuti abvumire kubviswa kuri nyore kana mhedzisiro yakakura ikamuka.
Mishonga inonangana nenzira dzakanangana muCRS kana neurotoxicity iri kuedzwa pamwe chete neCAR T kurapa kuderedza kuita kwakanyanya.
Kudzikisa njodzi dzehupfu, CAR T cell doses uye zvirongwa zvekurapa zviri kugadzirwa zvinoenderana nehunhu hwemurwere.
Semuenzaniso, chirongwa chePhase I / II (NCT04552054) uchishandisa BCMA-yakanangana neCAR T cell ine "jini rekuzviuraya" muvarwere vakawanda vemyeloma vakaratidza kuchengeteka uye kudzora CRS, pamwe nekukurudzira kubudirira kwemigumisiro.
Kuwana Mhinduro Dzakasimba
Dambudziko: CAR T cell therapy inoramba ichitarisana nematambudziko mukuchengetedza kudzora kwenguva refu bundu uye kudzivirira kudzoka zvakare.
Kufambira mberi: Kuedza kuri kuenderera mberi kuvandudza kushingirira uye hupenyu hwesero eCAR T:
Miedzo iri kuitwa pamaseru eCAR T akagadziridzwa kuti amise ndangariro basa, izvo zvinogona kutungamira kune-kureba-kwenguva anti-bundu zviito.
Nzira dzekukurudzira kuwedzera masero eCAR T mukati memuviri wemurwere zvichitevera kuisirwa kuri kuferefetwa kuti vawedzere kushingirira uye kushanda nesimba.
Vatsvakurudzi vari kutarisa mukubatanidza masero eCAR T nemamwe madhiragi ekudzivirira muviri kuti ape mhinduro inogara kwenguva refu inopesana netumor.
Semuenzaniso, chirongwa chePhase I/II (NCT04418739) chekuongorora CD19-yakanangwa CAR T sero ine ndangariro yekugona muB-cell leukemia yakaratidza inopfuurira mhinduro dzakakwana munhamba huru yevarwere mushure memwedzi gumi nemaviri, zvichiratidza kushanda kwenguva refu.
CARsgen's Inosimudzira Kenza Kuchengeta Nekunongedza Mapuroteni MuMamota Akasimba Akasiyana
CARsgen Therapeutics Holdings Limited nguva pfupi yadarika yakaratidza zviitiko zvikuru mushanduko yavo yeCAR T-cell therapy, CT041, pa2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Iyo kambani yakaratidza mhedzisiro yakanaka kubva kuPhase 1b ELIMYN18.2 tsvagiridzo, iyo yakanangana nesatricabtagene autoleucel (satri-cel), autologous CAR-T chigadzirwa mumiriri akanangana kurwisa Claudin18.2, puroteni yakaonekwa mune mamwe mamota akasimba.
CARsgen yakasimbisa kuchengetedzeka uye kushanda kwe satri-cel, zvichiratidza chimiro chinovimbisa. Iyo Yakakurudzirwa Phase 2 Dose (RP2D) yakatemerwa uye parizvino iri muChikamu 1b/2 kiriniki miedzo yekurapa advanced gastric / gastroesophageal junction (GC / GEJ) uye pancreatic cancer.
Ichi chidzidzo chekiriniki chakanangana neyakachengetedzeka chimiro chekuchengetedza, kushaikwa kwezvakakomba mhedzisiro, uye inokurudzira kubudirira, ine mhedzisiro yakakura kune varwere vane GC/GEJ nePC.
Satri-cel kugona semushonga wekurapa kweaya akaoma cancer ari kuramba achionekwa, zvichiratidza danho rakakosha kumberi mumunda weCAR T-cell kurapwa.
Ramangwana reCAR T Cell Therapy Clinical Trials MuChina
Ramangwana reCAR T cell therapy muChina rinoita serakajeka, rinotungamirwa nekuvhiya kwemiedzo uye kuzvipira kune hunyanzvi. Nepo pari zvino paine zvinopfuura zana zvidzidzo zvekiriniki zvakanangana nelymphoma chete, vaongorori vari kuwedzera kupfuura kenza yeropa, nemiedzo ya100 inorapa mamota akasimba vachishandisa nzira dzakasiyana senge mbiri mbiri dzeCAR uye dzakagadzirirwa munhu. TIL kurapa.
Vatsvagiri veChinese vari kutanga gene-akagadziridzwa "majini ekuzviuraya" uye vakananga kupindira kwemishonga, nezvakawanikwa zvekutanga zvinoratidza maprofile akanaka ekuchengetedza. Mutengo unoramba uri chipingamupinyi, asi masero eCAR T anogadzirwa munharaunda uye nzira itsva dzekugadzira dzinopa tariro yekuwanikwa kwakanyanya.
Kudyidzana nedzimwe nyika, uye hurumende yeChina iri kufambisa budiriro iyi, China ichironga kupa 10% yemishonga mitsva yeCAR T pasi rose panosvika 2030.
Iyi nzira yakazara, pamwe nekufambira mberi nekukurumidza, inoratidza ramangwana rakajeka revarwere vegomarara kwete muChina chete asi pasirese.
